304 related articles for article (PubMed ID: 31721602)
21. A review of berotralstat for the treatment of hereditary angioedema.
Farkas H; Balla Z
Expert Rev Clin Immunol; 2023 Feb; 19(2):145-153. PubMed ID: 36408587
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency.
Bork K; Bernstein JA; Machnig T; Craig TJ
J Emerg Med; 2016 Apr; 50(4):567-80.e1. PubMed ID: 26826769
[TBL] [Abstract][Full Text] [Related]
23. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
Zuraw BL; Maurer M; Sexton DJ; Cicardi M
Allergol Int; 2023 Jan; 72(1):54-62. PubMed ID: 35787344
[TBL] [Abstract][Full Text] [Related]
25. Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate.
Riedl MA; Hinds DR; Prince PM; Alvord TM; Dosenovic S; Abdelhadi JF; Brownrigg JR; Camp CL; Machnig T; Banerji A
Allergy Asthma Proc; 2023 Jul; 44(4):275-282. PubMed ID: 37328263
[No Abstract] [Full Text] [Related]
26. Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema.
Valerieva A; Caccia S; Cicardi M
Expert Rev Clin Immunol; 2018 Sep; 14(9):707-718. PubMed ID: 30021471
[TBL] [Abstract][Full Text] [Related]
27. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
[TBL] [Abstract][Full Text] [Related]
28. Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study.
Buttgereit T; Vera C; Weller K; Gutsche A; Grekowitz EM; Aykanat S; Wahn V; Krüger R; Maurer M; Magerl M
J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3744-3751. PubMed ID: 34023564
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hereditary angioedema-single or multiple pathways to the rescue.
Valerieva A; Longhurst HJ
Front Allergy; 2022; 3():952233. PubMed ID: 36172291
[TBL] [Abstract][Full Text] [Related]
30. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.
Wu MA; Zanichelli A; Mansi M; Cicardi M
Expert Opin Pharmacother; 2016; 17(1):27-40. PubMed ID: 26512744
[TBL] [Abstract][Full Text] [Related]
31. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
[TBL] [Abstract][Full Text] [Related]
32. Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema.
Riedl MA; Lumry WR; Li HH; Craig TJ; Fitts D; Kalfus I; Uknis ME
Am J Rhinol Allergy; 2013; 27(6):517-21. PubMed ID: 24274230
[TBL] [Abstract][Full Text] [Related]
33. The safety of treatments for angioedema with hereditary C1 inhibitor deficiency.
Zanichelli A; Wu MA; Andreoli A; Mansi M; Cicardi M
Expert Opin Drug Saf; 2015; 14(11):1725-36. PubMed ID: 26429506
[TBL] [Abstract][Full Text] [Related]
34. Investigational drugs in phase I and phase II clinical trials for hereditary angioedema.
Farkas H; Debreczeni ML; Kőhalmi KV
Expert Opin Investig Drugs; 2018 Jan; 27(1):87-103. PubMed ID: 29226721
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema.
Wang Y; Marier JF; Kassir N; Chang C; Martin P
Clin Transl Sci; 2020 Nov; 13(6):1208-1216. PubMed ID: 32407574
[TBL] [Abstract][Full Text] [Related]
36. [Experiencia inicial de Lanadelumab en una paciente mexicana con angioedema hereditario tipo I].
García-Rosas C; López-Tiro JJ; Contreras-Contreras A; Ruiz-Peñaloza M; Ortiz-Monteón ZE
Rev Alerg Mex; 2023 Sep; 70(4):194. PubMed ID: 37933935
[TBL] [Abstract][Full Text] [Related]
37. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.
Gower RG; Lumry WR; Davis-Lorton MA; Johnston DT; Busse PJ
Allergy Asthma Proc; 2012; 33(3):235-40. PubMed ID: 22584192
[TBL] [Abstract][Full Text] [Related]
38. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
39. Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries.
Guo Y; Zhang H; Lai H; Wang H; Chong-Neto HJ; Valle SOR; Zhu R
Orphanet J Rare Dis; 2022 Nov; 17(1):399. PubMed ID: 36324138
[TBL] [Abstract][Full Text] [Related]
40. Nanofiltered human C1 inhibitor concentrate (Cinryze®): in hereditary angioedema.
Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):317-27. PubMed ID: 21942916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
